

	<b>Normal</b>	<b>Diabetic with no DR</b>	<b>Diabetic with NPDR</b>	<b>Diabetic with PDR</b>
<b>CS</b>	<b>233.34±29.15</b>	<b>221.38±24.26</b>	<b>231.30±29.34</b>	<b>256.48±39.62</b>
<b>IS</b>	<b>296.52±20.40</b>	<b>290.74±18.73</b>	<b>280.52±31.90</b>	<b>296.88±23.42</b>
<b>IN</b>	<b>299.66±17.90</b>	<b>293.02±16.81</b>	<b>278.74±28.86</b>	<b>313.60±26.04</b>
<b>II</b>	<b>296.18±17.62</b>	<b>288.96±21.99</b>	<b>284.02±29.71</b>	<b>307.54±28.76</b>

**Table 1 : clinical and demographic data of all subjects**  
 (\*)= mean ± SD

<b>Parameters</b>	<b>Normal control</b>	<b>Diabetic with No DR</b>	<b>Diabetic with NPDR</b>	<b>Diabetic with PDR</b>
Age* (years)	<b>46.72±14.00</b>	<b>57.38±11.29</b>	<b>57.10±6.94</b>	<b>52.96±7.32</b>
(Male/Female) Percent	<b>17/33 34%:66%</b>	<b>14/36 28%:72%</b>	<b>16/34 32%:68%</b>	<b>26/24 52%:48%</b>
BCVA* (logmar)	<b>0.42±0.18</b>	<b>0.62±0.23</b>	<b>0.86±0.19</b>	<b>1.00±0.17</b>
Duration of DM*	-	<b>5.48±4.39</b>	<b>13.96±4.93</b>	<b>14.70±4.17</b>
Insulin/oral treatment Percent	-	<b>12/38 24%:76%</b>	<b>35/15 70%:30%</b>	<b>31/19 62%:38%</b>

IT	286.84±18.12	282.78±17.68	274.52±31.97	294.92±30.91
OS	261.12±16.21	260.62±15.73	257.66±23.68	289.98±27.08
ON	273.76±17.86	276.24±16.10	263.32±30.03	293.78±33.01
OI	255.40±18.04	257.80±18.98	256.04±23.43	285.52±51.46
OT	248.22±15.73	249.44±18.11	251.67±23.46	284.04±38.55

Table (2) : Comparison between normal control and diabetic patient with varying degrees of diabetic retinopathy expressed as (mean ± SD )